Results 191 to 200 of about 2,345,783 (392)

Increased Extra‐Axial Cerebrospinal Fluid Volume in Children With Angelman Syndrome: Links to Sleep Problems and Seizures

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Background Previous studies demonstrated that children with autism have enlarged volumes of extra‐axial cerebrospinal fluid (EA‐CSF) and an increased ratio of EA‐CSF to brain volume, indicating that EA‐CSF is disproportionally increased beyond macrocephaly often observed in autism.
Zumin Chen   +10 more
wiley   +1 more source

Effectiveness of vagal nerve stimulation (VNS) in patients with drop-attacks and different epileptic syndromes [PDF]

open access: bronze, 2011
Nicola Zamponi   +4 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan   +6 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams   +7 more
wiley   +1 more source

The Clinical and Genetic Landscape of a French Multicenter Cohort of 2563 Epilepsy Patients Referred for Genetic Diagnosis. [PDF]

open access: yesEur J Neurol
de Sainte Agathe JM   +52 more
europepmc   +1 more source

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM).
Andriy A. Gorbenko   +7 more
wiley   +1 more source

A novel germline PIGA mutation in Ferro‐Cerebro‐Cutaneous syndrome: A neurodegenerative X‐linked epileptic encephalopathy with systemic iron‐overload [PDF]

open access: green, 2013
Kathryn J. Swoboda   +11 more
openalex   +1 more source

Home - About - Disclaimer - Privacy